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In last two decades, the field of drug metabolism and pharmacokinetics (DMPK) has been considerably 
improved due to various reasons, i.e., routine incorporation of DMPK into early drug discovery, better 
understanding of drug dispositional elements (drug metabolizing enzymes and uptake/efflux transporters) 
and implementation of optimized DMPK properties in preclinical drug discovery and development. In this 
regard, both in vitro and in vivo experimental tools play significant role to understand different critical 
Absorption, Distribution, Metabolism and Elimination (ADME) parameters which accelerated tremendously 
the lead selection, lead optimization and the preclinical development of the drug candidate prior to the 
clinical trials. Among these experimental tools, in vitro assays are quite advantageous in comparison to the 
in vivo models because of its convenient and economical way to address the specific questions in short 
time period. These in vitro experimental models are often employed to determine the nature of enzyme 
induction/inhibition (mainly CYPs) in drug-drug interaction (DDI) studies, metabolite identification, reaction 
phenotyping and elucidation of the biotransformation/metabolic pathway of new chemical entities (NCEs) 
[1, 2]. Although it has been shown that due to species related differences, preclinical species cannot always 
predict human CYP induction/inhibition; nonetheless a good in vitro-in vivo correlation has always been 
observed when human based in-vitro assays have been employed [3]. 
In case of metabolite identification and enzyme kinetic studies, the best way to investigate the 
metabolic profile of the drug in a certain tissue is to procure the tissue specimen and evaluate the activity. 
In case of liver, this particular method has been applied successfully and undoubtedly this is the method of 
choice to gain information on hepatic drug metabolism. However, in order to extrapolate the research 
findings in human, we need to consider additional factors such as ethics, sampling procedure and 
bioanalysis etc. In addition, although a normal liver is imperative for the research purpose, in reality most 
of the human liver material is pathological to some extent. Depending on what kind of questions we want 
to address, a variety of different preparations can be used, such as a fully physiological preparation (e.g. a 
whole perfused liver) or a strictly biochemical preparation (e.g. cellular sub-fractions such as microsomes) 
or a compromise situation (e.g. liver slices, cubes and hepatocytes etc.).  
Among all the established in vitro experimental tools, microsomes are the mostly widely used 
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subcellular fractions for drug metabolism studies as it is inexpensive and easy to handle [4]. Microsomal 
assays are the default assays for metabolism and DDI studies at the drug discovery stage [5]. In order to 
determine intrinsic clearance of NCEs, which is a useful parameter for screening process of stable 
compounds and for establishing an in vitro correlation between animals and humans, microsomal assays 
play significant role. In addition, this assay can also be utilized to assess extra-hepatic metabolism and 
determine the DDI potential of the drug candidate in preclinical phase [6]. Apart from liver, microsomes 
can also be utilized to focus on the region-specific activity of the intestinal enzymes. In general, the 
experimental conditions utilizing microsomes can be easily controlled in comparison to in vivo and in situ 
models. Moreover, these methods are theoretically applicable to all species and can be used to study 
phase I and phase II drug metabolism to get the enzyme isoforms activity profile [7, 8]. There are few 
limitations of microsomes, for instance, they have to be supplied with co-factors like NADPH, or UDPGA for 
the metabolic reactions to initiate, and lack the cell membranes to mimic the physiological environment in 
hepatocytes [7, 8]. In addition, it suffers from its non-physiological nature due to the absence of cellular 
metabolism, membrane transport and production of co-factor [3, 9]. Furthermore, this tissue preparation 
cannot provide the information on the activities of the transporters along the intestine, which can be 
critical for the investigation of gut metabolism to rationalize the absorption and permeability of the 
compound. The preparations of intestinal microsomes are more prone to artefacts in comparison to the 
preparation of the liver microsomes. 
Several attempts have been made to reach a mid-point between the physiological complexity and 
biochemical ease. For that effort, liver slices as well as isolated cells have been used. Liver slices have the 
physiological cell to cell contact needed for the liver preparation but are somewhat unsatisfactory due to 
the inability to get access of the substrate and nutrient to the centre of the preparation. In comparison, 
isolated liver cells are regarded as the best alternate, as they can be stored in cultures for extended periods 
of time without losing their differentiated functions. Due to the presence of various uptake or efflux 
transporters in hepatocyte cell membranes, this particular subcellular fraction can be used to determine 
the role of transporter on the disposition of NCE in preclinical discovery phase. The primary culture of 
hepatocytes provides a physiological environment that closely mimics the in vivo conditions as it contains 
enzyme and co-factors at physiological concentrations. In drug discovery, hepatocytes are mainly used as 
sandwich cultures or suspensions which are primarily used for the study of metabolic stability or 
transporter-mediated uptake of drug candidates. Like microsomes, hepatocytes can also be used in DDI 
predictions and in determining intrinsic clearance. However, the major application of cultured hepatocytes 
is in CYP induction studies as enzyme induction may involve gene transcription and translation [10]. 
Despite hepatocytes playing a significant role in drug discovery, their application is to some extent limited 
because they are not readily available and difficult to reproduce the results due to high inter individual 
variability between human liver donors. Of late, freshly isolated, pooled cryopreserved hepatocytes are 
being used to circumvent this problem which allows researchers to use the same lot of cells over a period 
of time. However, improving long term culture of hepatocyte has been an area of research focus in the last 
decade.  
In the cell system, drugs never have easy access to the drug metabolizing enzymes. They have to pass 
through barriers containing drug transporters which facilitate the movement of these drugs across the 
membrane either concentrating the cell via influx transporters, or dispersing the drug through efflux 
transporters denying access of enzymes to the drug [11]. Due to the involvement of these drug 
transporters, in drug disposition and DDIs, there has been major interest in the past decade to study the 
role of these transporters in drug discovery and development. Hepatocytes have a cellular organization 
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containing the necessary co-factors and membranes transporters, which represent a more complete 
system to study drug metabolism. Due to the high cost and the complexity in conducting experiments with 
hepatocytes, microsomes still remain the tool of choice for early drug discovery studies. Due to the 
advancement of technology, commercial companies and research organizations can now obtain human 
livers, make and store deep frozen slices and isolated hepatocytes in research and drug testing. From the 
literature studies it is quite evident that instead of following a general method to procure and utilizing the 
tissue, a case by case approach has always been taken depending on what kind of questions we would like 
to answer, physiological or biochemical. For an example, in order to measure the change of phase I or II 
drug metabolizing enzyme content, the usage of microsomes or other subcellular fraction is appropriate. 
On the other hand, to assess the impact of transporters on the disposition of NCEs in discovery phase as 
well as to investigate the presence or nature of hepatotoxicity, hepatocytes or whole liver preparation will 
be more useful. Reverting back to the title of this opinion “Is there a Paradigm Shift in use of Microsomes 
and Hepatocytes in Drug Discovery and Development?”; based on the literature, even though utilization of 
hepatocytes in drug discovery and development has been increasing in the last decade, the choice of in 
vitro tool mainly depends on the type of study performed. 
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